When 62-year-old James Holloway began feeling constantly fatigued, losing muscle mass, and struggling with low energy, his doctor in Columbus, Ohio, suggested testosterone replacement therapy—a treatment once clouded by cautionary labels that may soon be rewritten. In Washington, D.C., the U.S. Food and Drug Administration (FDA), acting on behalf of the Department of Health and Human Services (HHS), is proposing significant updates to how testosterone therapies are labeled, reflecting new scientific clarity from one of the largest clinical trials on the subject to date. These changes could reshape how millions of men across the U.S. access and understand this widely used treatment.
For years, men like Holloway faced restrictive language on drug labels suggesting testosterone therapy was unproven for age-related low testosterone, a condition affecting an estimated 2 million men annually. That stance, put in place in 2015 amid concerns about cardiovascular risks, may soon be lifted. The FDA’s reconsideration follows the TRAVERSE trial, a landmark study involving more than 5,200 men, which found no significant increase in major cardiovascular events—such as heart attacks or strokes—among those receiving testosterone therapy. This robust evidence has led regulators to conclude that the previous limitations are no longer scientifically justified.
Equally significant are the proposed changes to prostate cancer warnings. Current labels outright discourage use in men with suspected or existing prostate cancer, but the new guidance would allow use in all cases except metastatic prostate cancer. While long-standing fears linked testosterone to prostate cancer progression, recent clinical and population studies have largely failed to confirm that risk. Still, the FDA emphasizes caution: doctors will still be urged to screen patients before treatment and monitor them closely throughout. The update on benign prostatic hyperplasia (BPH) is similarly nuanced—while evidence shows testosterone doesn’t worsen symptoms in men with mild to moderate enlarged prostate, monitoring is still recommended for those with severe cases.
"FDA's responsibility is to ensure prescribing information reflects the best available scientific evidence," said Dr. Michael Davis, acting director of the FDA's Center for Drug Evaluation and Research. "These updates provide patients and health care professionals with clearer information about the benefits and risks of testosterone replacement therapy and support informed treatment decisions." As science evolves, so too must medical guidance, ensuring that patients and providers navigate treatment with confidence, not outdated fear. For men like Holloway, that clarity could mean regaining vitality with greater peace of mind.